CD3+<192,3x106/kg (n=19)	CD3+>192,3x106/kg (n=19)	p value
AGE // GENDER (M/F)	59 (24-70) // 13 (68,4%) / 6 (31,6%)	40 (19-65) // 10 (52,6%) / 9 (47,4%)	0,041 / 0,319
CONDITIONING: BUCY / FLUBU / CY-TBI	12 (63,2%) / 6 (31,6%) / 1 (5,2%)	13 (68,4%) / 3 (15,8%) / 3 (15,8%)	0,210
ABO COMPATIBILITY: COMPATIBLE / MAJOR / MINOR	11 (57,9%) / 4 (21,1%) / 4 (21,1%)	9 (47,4%) / 5 (26,3%) / 5 (26,3%)	0,810
DISEASE STATUS: CR / CR MRD+ / ACTIVE	11 (57,9%) / 6 (31,6%) / 2 (10,5%)	14 (73,7%) / 4 (21,1%) / 1 (5,2%)	0,579
CMV STATUS(D/R): +/+ // +/- // -/+ // -/-	12 (63,2%) / 0 / 6 (31,6%) / 1 (5,2%)	6 (31,6%) / 3 (15,8%) / 9 (47,4%) /1 (5,2%)	0,133
SEX STATUS (D/R): M/M // M/F // F/M // F/F	9 (47,4%) / 5 (26,3%) / 3 (15,8%) / 2 (10,5%)	7 (36,8%) / 3 (15,8%) / 3 (15,8%) 6 (31,6%)	0,432
GVHD PROPHYLAXIS: CSA + MTX / CSA + MTX + ATG	19 (100%) / 0	18 (94,7%) / 1 (5,2%)	1,000
CD34+x106/kg	6 (3,2-7,2)	6 (3-6,6)	0,799
ENGRAFMENT (DAYS) LEUKOCYTE / PLATELETS	20 (11-31) / 14 (10-41)	17 (12-29) / 14 (8-54)	0,084 / 0,632